Brain metastases in the elderly – Impact of residual tumor volume on overall survival

Background Due to demographic changes and an increased incidence of cancer with age, the number of patients with brain metastases (BMs) constantly increases, especially among the elderly. Novel systemic therapies, such as immunotherapy, have led to improved survival in recent years, but intracranial tumor progression may occur independently of a systemically effective therapy. Despite the growing number of geriatric patients, they are often overlooked in clinical trials, and there is no consensus on the impact of BM resection on survival. Objectives The aim of this study was to analyze the impact of resection and residual tumor volume on clinical outcome and overall survival (OS) in elderly patients suffering from BM. Methods Patients ≥ 75 years who had surgery for BM between April 2007 and January 2020 were retrospectively included. Residual tumor burden (RTB) was determined by segmentation of early postoperative brain MRI (72 h). Contrast-enhancing tumor subvolumes were segmented manually. “Postoperative tumor volume” refers to the targeted BMs. Impact of preoperative Karnofsky performance status scale (KPSS), age, sex and RTB on OS was analyzed. Survival analyses were performed using Kaplan-Meier estimates for the univariate analysis and the Cox regression proportional hazards model for the multivariate analysis. Results One hundred and one patients were included. Median age at surgery was 78 years (IQR 76-81). Sixty-two patients (61%) had a single BM; 16 patients (16%) had two BMs; 13 patients (13%) had three BMs; and 10 patients (10%) had more than three BMs. Median preoperative tumor burden was 10.3 cm3 (IQR 5–25 cm3), and postoperative tumor burden was 0 cm3 (IQR 0–1.1 cm3). Complete cytoreduction (RTB = 0) was achieved in 52 patients (52%). Complete resection of the targeted metastases was achieved in 78 patients (78%). Median OS was 7 months (IQR 2–11). In univariate analysis, high preoperative KPSS (HR 0.986, 95% CI 0.973–0.998, p = 0.026) and small postoperative tumor burden (HR 1.025, 95% CI 1.002–1.047, p = 0.029) were significantly associated with prolonged OS. Patients with RTB = 0 survived significantly longer than those with residual tumor did (12 [IQR 5–19] vs. 5 [IQR 3–7] months, p = 0.007). Furthermore, prolongation of survival was significantly associated with surgery in patients with favorable KPSS, with an adjusted HR of 0.986 (p = 0.026). However, there were no significances regarding age. Conclusions RTB is a strong predictor for prolonged OS, regardless of age or cancer type. Postoperative MRI should confirm the extent of resection, as intraoperative estimates do not warrant a complete resection. It is crucial to aim for maximal cytoreduction to achieve the best long-term outcomes for these patients, despite the fact the patients are advanced in age.

[1]  S. Combs,et al.  The Impact of Postoperative Tumor Burden on Patients With Brain Metastases , 2022, Frontiers in Oncology.

[2]  J. Landsberg,et al.  Outcome of Elderly Patients With Surgically Treated Brain Metastases , 2021, Frontiers in Oncology.

[3]  M. Ruge,et al.  Brain Metastases in Elderly Patients—The Role of Surgery in the Context of Systemic Treatment , 2021, Brain sciences.

[4]  T. Huber,et al.  Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor? , 2020, BMC Neurology.

[5]  T. Geeraerts,et al.  Editorial. Geriatric neurosurgery: the unfolding of a new subspecialty. , 2020, Neurosurgical focus.

[6]  H. Steiger,et al.  Risk factors for in-brain local progression in elderly patients after resection of cerebral metastases , 2019, Scientific Reports.

[7]  Timothy R. Smith,et al.  Survival and prognostic factors in surgically treated brain metastases , 2019, Journal of Neuro-Oncology.

[8]  A. Moiyadi,et al.  Surgery for brain metastases: An analysis of outcomes and factors affecting survival , 2018, Clinical Neurology and Neurosurgery.

[9]  J. Buckner,et al.  Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  P. Brown,et al.  The Diminishing Role of Whole-Brain Radiation Therapy in the Treatment of Brain Metastases , 2017, JAMA oncology.

[11]  Alexander Radbruch,et al.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.

[12]  M. Balbín,et al.  Prognostic factors and survival study in high-grade glioma in the elderly , 2016, British journal of neurosurgery.

[13]  R. Loffeld,et al.  Impact of age and comorbidity on survival in colorectal cancer. , 2015, Journal of gastrointestinal oncology.

[14]  Martin Bendszus,et al.  Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.

[15]  E. Mandonnet,et al.  Evolution of the Karnosky Performance Status throughout life in glioblastoma patients , 2015, Journal of Neuro-Oncology.

[16]  Amy S Nowacki,et al.  Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. , 2014, Journal of neurosurgery.

[17]  P. Brown,et al.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. , 2013, Neuro-oncology.

[18]  A. Olivi,et al.  Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. , 2011, Journal of neurosurgery.

[19]  D. Scheie,et al.  Intracranial tumor surgery in patients >70 years of age: is clinical practice worthwhile or futile? , 2009, Acta neurologica Scandinavica.

[20]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[21]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[22]  G. Becker,et al.  Is older age associated with a worse prognosis due to different patterns of care? , 2005, Cancer.

[23]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[24]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[25]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[26]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[27]  E. Noordijk,et al.  The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. , 1994, International journal of radiation oncology, biology, physics.